2023³â Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãß°è Çмú´ëȸ ¹× ¿¬¼ö±³À°
2023³â 11¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå ±èÁ¾¿ì
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå ÇÏÁöÇö
»çÀüµî·Ï | ´çÀϵî·Ï | ºñ°í | |
---|---|---|---|
|
|
|
Áß½ÄÁ¦°ø |
* Àü¹®°¡°úÁ¤À» ¼ö·áÇϽŠ¼±»ý´Ôµéµµ Æò»ýȸ¿ø°¡ÀÔÀ» ÇÏÁö ¾ÊÀ¸½Å °æ¿ì´Â µî·Ïºñ ¸éÁ¦¿¡ ÇØ´çÇÏÁö ¾ÊÀ¸½ÉÀ» ¾Ë·Áµå¸³´Ï´Ù.
PROGRAM | ||
09:00-09:20 | µî·Ï | |
09:20-09:30 | °³È¸»ç | ±èÁ¾¿ì / ȸÀå, °æÈñÀÇ´ë |
Àλ縻 | ÇÏÁöÇö / ÀÌ»çÀå, °Ç±¹ÀÇ´ë |
ÄÁº¥¼ÇȦ | ´ëȸÀÇ½Ç | ||||
Çмú´ëȸ | ¿¬¼ö±³À° | ||||
Symposium 1 New updates on women¡¯s mental health |
ÁÂÀå : ±èÁ¾¿ì °æÈñÀÇ´ë / °í¿µÈÆ °í·ÁÀÇ´ë |
¿¬¼ö±³À° I ½ÅüÁõ»óÀå¾ÖÀÇ Áø´Ü°ú Ä¡·á |
ÁÂÀå : ¼Á¤¼® Áß¾ÓÀÇ´ë / °¿ø¼· °æÈñÀÇ´ë | ||
09:30-09:55 | Psychosomatic and vasomotor symptom changes during transition to menopause | À̾ƶó °æÈñÀÇ´ë | 09:55-10:20 | ½ÅüÁõ»óÀå¾ÖÀÇ Æò°¡ ¹× °¨º°Áø´Ü | ±èÈñÁø Áß¾ÓÀÇ´ë |
---|---|---|---|---|---|
09:55-10:20 | Management of premenstrual syndrome and premenstrual dysphoric disorder | Á¤»çÀÓ °í·ÁÀÇ´ë | |||
10:20-10:45 | Update on postpartum depression: FDA Approves firstoral treatment for postpartum depression | È«Á¤¿Ï Àͻ꺴¿ø | 10:20-10:45 | ½ÅüÁõ»óÀå¾ÖÀÇ ¾à¹°Ä¡·á ¹× Á¤½ÅÄ¡·á | Àӿ쿵 °Ç¾çÀÇ´ë |
10:45-10:55 | Q&A | 10:20-10:45 | Q&A | ||
10:55-11:05 | Coffee break | 10:55-11:05 | Coffee break | ||
Symposium II Unraveling the relation of depression with somatic conditions |
ÁÂÀå : ÀÌ»ó¿ ¿ø±¤ÀÇ´ë / Àü´öÀÎ ÇѸ²ÀÇ´ë |
¿¬¼ö±³À° II ÀüȯÀå¾Ö(±â´É¼º ½Å°æÇÐÀû Áõ»ó Àå¾Ö)ÀÇ Áø´Ü°ú Ä¡·á |
ÁÂÀå : ¼ÛÁö¿µ ¼¿ï¼º½Éº´¿ø / Á¤Á¾Çö °¡Å縯ÀÇ´ë | ||
11:05-11:30 | Depression preceding Parkinson¡¯s disease: Risk factor or early symptoms? | ½Åö¹Î °í·ÁÀÇ´ë | 11:05-11:30 | ÀüȯÀå¾ÖÀÇ Æò°¡ ¹× °¨º°Áø´Ü | À±¼¿µ °¡Å縯ÀÇ´ë |
11:30-11:55 | Depression in rheumatic disease and the role of disease-related factors | °¿ø¼· °æÈñÀÇ´ë | 11:30-11:55 | ÀüȯÀå¾ÖÀÇ ¾à¹°Ä¡·á¿Í Á¤½ÅÄ¡·á | ÃÖÀç¿ø À»ÁöÀÇ´ë |
11:55-12:20 | Depression with glycemic control in diabetic patients | ¼Û¹Î±Ô ¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаú | |||
12:20-12:30 | Q & A | 12:20-12:30 | Q & A | ||
Luncheon Symposium | ÁÂÀå : ÀÌ°ÁØ ÀÎÁ¦ÀÇ´ë | ||||
12:30-13:30 | Olanzapine Efficacy for Anxiety, Agitation, and Sleep Disturbances in Mood Disorders | ÀüÈ«ÁØ °Ç±¹ÀÇ´ë | |||
13:30-13:40 | Coffee break | ||||
Çмú´ëȸ | ¿¬¼ö±³À° | ||||
Symposium III Agitation in specific population |
ÁÂÀå : ±èÁ¾Èç ±¹¸³¾Ï¼¾ÅÍ / ±èÀÇÁß À»ÁöÀÇ´ë |
¿¬¼ö±³À° III Ÿ°ú¿¡¼ ÈçÈ÷ ÀÚ¹® ÀǷڵǴ Case »ç·ÊÁ᫐ (´Ù¸¥ ÀÇÇÐÀû »óÅÂ¿Í µ¿¹ÝµÇ´Â Á¤½Å°úÀû Áõ»ó) |
ÁÂÀå : ±èÁ¤Çö ¼¿ïÀÇ´ë / À̹®¼ö °í·ÁÀÇ´ë | ||
13:40-14:05 | Agitation from a general medical condition: Medical evaluation of agitated patient | ÀÌ°æȯ ºÀ»ý±â³äº´¿ø | 13:40-14:05 | ¼ÒȱâÁúȯ | Áö¼öÇõ °í·ÁÀÇ´ë |
14:05-14:30 | Agitation and aggression in dementia patients | ¾öÀ¯Çö °¡Å縯ÀÇ´ë | 14:05-14:30 | ½ÅÀåÁúȯ | ±è°æ¹Î °æºÏÀÇ´ë |
14:30-14:55 | Treatment of agitation following traumatic brain injury | ¾çÇöÁÖ Á¦ÁÖÀÇ´ë | 14:30-14:55 | ·ù¸¶Æ¼½ºÁúȯ | ±è¿øÇü ÀÎÇÏÀÇ´ë |
14:55-15:05 | Q & A | 14:55-15:20 | ¾Ï(Á¤½ÅÁ¾¾çÇÐ) | ¹ÚÇýÀ± ¼¿ïÀÇ´ë | |
15:05-15:15 | Coffee break | 15:20-15:30 | Q & A | ||
Symposium IV Outstanding research in psychosomatic field |
ÁÂÀå : ÇÏÁöÇö °Ç±¹ÀÇ´ë / Á¤¼®ÈÆ ¿ï»êÀÇ´ë | ||||
15:15-15:40 | Panic Disorder Reconsidered: Delineating Its Status as an utonomous Entity Versus a Non-Specific Stress Reaction Through the Lens of Comorbidity Studies | ÀüÈ«ÁØ °Ç±¹ÀÇ´ë | |||
15:40-16:05 | Digital Health Service for Cancer Survivors: Personalized Information and Coaching for Healthy Living | ±è¼±¹Ì Áß¾ÓÀÇ´ë | |||
16:05-16:30 | Recent updates in delirium research | ¿ÀÁÖ¿µ ¿¬¼¼ÀÇ´ë | |||
16:30-16:40 | Q&A | ||||
16:40- | Æóȸ ¹× Á¤±âÃÑȸ |
2023³â Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°è Çмú´ëȸ ¹× ¿¬¼ö±³À°
2023³â 5¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå ÇÑâ¼ö
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå ÇÏÁöÇö
»çÀüµî·Ï | ´çÀϵî·Ï | ºñ°í | |
---|---|---|---|
|
|
|
Áß½ÄÁ¦°ø |
* Àü¹®°¡°úÁ¤À» ¼ö·áÇϽŠ¼±»ý´Ôµéµµ Æò»ýȸ¿ø°¡ÀÔÀ» ÇÏÁö ¾ÊÀ¸½Å °æ¿ì´Â µî·Ïºñ ¸éÁ¦¿¡ ÇØ´çÇÏÁö ¾ÊÀ¸½ÉÀ» ¾Ë·Áµå¸³´Ï´Ù.
PROGRAM | ||
09:00-09:20 | µî·Ï | |
09:20-09:30 | °³È¸»ç | ÇÑâ¼ö / ȸÀå, °í·ÁÀÇ´ë |
Àλ縻 | ÇÏÁöÇö / ÀÌ»çÀå, °Ç±¹ÀÇ´ë |
ÄÁº¥¼ÇȦ | ´ëȸÀÇ½Ç | ||||
Çмú´ëȸ | ¿¬¼ö±³À° | ||||
Symposium 1 Clinical and Research Update on Delirium |
ÁÂÀå : ÇÏÁöÇö °Ç±¹ÀÇ´ë / Àü´öÀÎ ÇѸ²ÀÇ´ë |
¿¬¼ö±³À° I ÀӽŠ°ü·Ã ¿ì¿ïÁõ Ä¡·áÀÇ ÃֽŠ°æÇâ |
ÁÂÀå : ±èÀÇÁß À»ÁöÀÇ´ë / ±èż® °¡Å縯ÀÇ´ë | ||
09:30-09:55 | Pathophysiology and biomarker of delirium | ½Åö¹Î °í·ÁÀÇ´ë | 09:30-09:55 | ¾à¹°Ä¡·á | ȲÇöÂù Áß¾ÓÀÇ´ë |
---|---|---|---|---|---|
09:55-10:20 | Assessment and prevention of delirium | ¹ÚÇý¿¬ ¼¿ïÀÇ´ë | 09:55-10:20 | ³úÀÚ±ØÄ¡·á | ¾öÀ¯Çö °¡Å縯ÀÇ´ë |
10:20-10:45 | An update on delirium management | Á¤»çÀÓ °í·ÁÀÇ´ë | 10:20-10:45 | ½É¸®Ä¡·á ¹× µðÁöÅÐÄ¡·á | ¹Ú¹ÌÁø ¼¿ï¼º¸ðº´¿ø |
10:45-10:55 | Q&A | 10:45-10:55 | Q&A | ||
10:55-11:05 | Coffee break | 10:55-11:05 | Coffee break | ||
Symposium II Clinical Comprehension on Treatment of FGID |
ÁÂÀå : ÀÌ»ó¿ ¿ø±¤ÀÇ´ë / À̹®¼ö °í·ÁÀÇ´ë |
¿¬¼ö±³À° II Á¤½Å°Ç°ÀÇÇаú Àǻ簡 ¾Ë¾Æ¾ß ÇÏ´Â ¸¸¼º ÅëÁõ Ä¡·á |
ÁÂÀå : Á¤Á¾Çö °¡Å縯ÀÇ´ë / ¼Á¤¼® Áß¾ÓÀÇ´ë | ||
11:05-11:30 | Medical approach and management of functional gastrointestinal disorders | ¹ÚÁ¤È£ °ºÏ»ï¼ºº´¿ø ¼Òȱ⳻°ú | 11:05-11:30 | ¸¸¼º ÅëÁõÀÇ ¾à¹°Ä¡·á | ±è¼±¹Ì Áß¾ÓÀÇ´ë |
11:30-11:55 | The Gut microbiome | ±è¿ë¼º ¿ø±¤ÀÇ´ë ¼ÒȱâÁúȯ ¿¬±¸¼Ò | 11:30-11:55 | ¸¸¼º ÅëÁõÀÇ ºñ¾à¹°Àû Ä¡·á | ±èÀçÇå °Ç±¹´ëº´¿ø ¸¶ÃëÅëÁõÀÇÇаú |
11:55-12:20 | Functional gastrointestinal disorders: an update for the psychiatrist | Àå½ÂÈ£ ¿ø±¤ÀÇ´ë | 11:55-12:20 | ¸¸¼º ÅëÁõÀÇ ½É¸®Ä¡·á | ³ªÀÇÇö ¿¹¼öº´¿ø |
12:20-12:30 | Q & A | 12:20-12:30 | Q & A | ||
Luncheon Symposium | ÁÂÀå : ÇÑâ¼ö °í·ÁÀÇ´ë | ||||
12:30-13:20 | Beyond Response : Aiming for Quality Remission in Depression | ÀüÈ«ÁØ °Ç±¹ÀÇ´ë | |||
13:30-13:40 | Poster tour | ||||
Plenary Lecture | ÁÂÀå : ÇÏÁöÇö °Ç±¹ÀÇ´ë | ||||
13:40-14:30 | From Reactive to Proactive: Evolution of Consultation-Liaison Psychiatry and Development of Rochester Mode | Hochang Benjamin Lee University of Rochester Medical Center | |||
14:30-14:40 | Coffee break | ||||
Mutual Visiting Program | ÁÂÀå : ±èÁ¾Èç ±¹¸³¾Ï¼¾ÅÍ | ||||
14:40-15:00 | Cognitive therapy using a smartphone app for the fear of cancer recurrence | Tatsuo Akechi Department of Psychiatry, Nagoya City University | |||
15:00-15:20 | Evaluation of the usefulness of a nurse-centered delirium care program | Noriko Shirai Department of Nursing, Kitasato University Hospital | |||
15:20-15:30 | Coffee break | ||||
Çмú´ëȸ | Çмú´ëȸ | ||||
Symposium III Recent Updates on Stress and Mental Disorder |
ÁÂÀå : ±èÁ¾¿ì °æÈñÀÇ´ë / ±èÁ¤Çö ¼¿ïÀÇ´ë |
Symposium IV Special Issues in Consultation-Liaison Psychiatry |
ÁÂÀå : ÀºÇåÁ¤ ÀºÇåÁ¤Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø / °í¿µÈÆ °í·ÁÀÇ´ë | ||
15:30-15:55 | Stress and allostatic load | °¿ø¼· °æÈñÀÇ´ë | 15:30-15:55 | Management of repeated self-harm and suicide attempt in children and adolescents | ±èÈñÁø Áß¾ÓÀÇ´ë |
15:55-16:20 | Measurement of stress | ¼®Á¤È£ ¿¬¼¼ÀÇ´ë | 15:55-16:20 | Psychiatric aspects of Kidney transplantation | À̾ƶó °æÈñÀÇ´ë |
16:20-16:45 | Stress and psychiatric disorders: from categorical to dimensional approaches | ¾çÇöÁÖ Á¦ÁÖÀÇ´ë | 16:20-16:45 | Psychiatric Management of Bariatric Surgery Patients | ³ªÁö¿ø ¿ø±¤ÀÇ´ë |
16:45-16:55 | Q&A | 16:45-16:55 | Q&A | ||
16:55- | ½Ã»ó½Ä ¹× ÃÑȸ |
2022³â Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãß°è Çмú´ëȸ ¹× ¿¬¼ö±³À°
2022³â 12¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå ÇÑâ¼ö
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå ÇÏÁö¿¬
»çÀüµî·Ï | ´çÀϵî·Ï | ºñ°í | |
---|---|---|---|
|
|
|
Áß½ÄÁ¦°ø |
*Àü¹®°¡°úÁ¤À» ¼ö·áÇϽŠ¼±»ý´Ôµéµµ Æò»ýȸ¿ø°¡ÀÔÀ» ÇÏÁö ¾ÊÀ¸½Å °æ¿ì´Â µî·Ïºñ ¸éÁ¦¿¡ ÇØ´çÇÏÁö ¾ÊÀ¸½ÉÀ» ¾Ë·Áµå¸³´Ï´Ù.
PROGRAM | ||
09:00-09:20 | µî·Ï | |
09:20-09:30 | °³È¸»ç | ÇÑâ¼ö / ȸÀå, °í·ÁÀÇ´ë |
Àλ縻 | ÇÏÁöÇö / ÀÌ»çÀå, °Ç±¹ÀÇ´ë |
A·ë | B·ë | ||||
¿¬¼ö±³À° »çȸ : ±è¼±¹Ì Áß¾ÓÀÇ´ë |
ÀÓ»ó³úÆÄÀ§¿øȸ ¿öÅ©¼¥ Epilepsy/Epilepsy Syndrome and Neuropsychiatry »çȸ : ÀºÇåÁ¤ ´ëÀÚÀκ´¿ø |
||||
¿¬¼ö±³À° 1 ¹°Áú»ç¿ëÀå¾ÖÀÇ »ý¹°Á¤½Å»çȸÀû ¸ðµ¨ : Æò°¡¿Í Ä¡·á¸¦ Áß½ÉÀ¸·Î |
ÁÂÀå : ±èÀÇÁß À»ÁöÀÇ´ë / ¼Á¤¼® Áß¾ÓÀÇ´ë |
Session¥° Overview of Epilepsy Syndrome |
ÁÂÀå : ÀºÇåÁ¤ ´ëÀÚÀκ´¿ø | ||
09:30-09:55 | Illicit Substance | õ¿µÈÆ ÀÎõÂü»ç¶ûº´¿ø | 09:30-09:55 | Classification of Epileptic Seizures and Epilepsy Syndrome | Á¤Á¾Çö °¡Å縯ÀÇ´ë |
---|---|---|---|---|---|
09:55-10:20 | Prescription Drugs- Opioids | ¹Ú½ÂÇö ´ë±¸´ëµ¿º´¿ø | 09:55-10:20 | Epileptogenesis | À̹̰æ ÀÌÁöºê·¹ÀÎÀÇ¿ø |
10:20-10:45 | Prescription Drugs- Sedatives and Stimulants | Àå¿ÁÁø ±¹¸³ºÎ°îº´¿ø | 10:20-10:45 | EEG in Epilepsy Syndrome | ÃÖÁØÈ£ ÇѾçÀÇ´ë |
10:45-10:55 | Q&A | 10:45-10:55 | Q&A | ||
10:55-11:05 | Coffee break | 10:55-11:05 | Coffee break | ||
¿¬¼ö±³À° 2 Á¤½Å°Ç°ÀÇÇаú ÀÇ»çÀÇ ºñ¸¸Ä¡·á |
ÁÂÀå : Àü´öÀÎ ÇѸ²ÀÇ´ë / Á¤Á¾Çö °¡Å縯ÀÇ´ë |
Session ¥± Neuropsychiatric Problems in Epilepsy and Epilepsy Syndrome |
ÁÂÀå : ÀÌ»ó¿ ¿ø±¤ÀÇ´ë | ||
11:05-11:30 | Á¤½Å°Ç°ÀÇÇаú Àǻ簡 ºñ¸¸À» Ä¡·áÇØ¾ß Çϴ°¡? | ¼Û¹Î±Ô ¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаú | 11:05-11:30 | Speech and Language Problems in Epilepsy Syndrome | ¹ÚÅ¿ø ÀüºÏÀÇ´ë |
11:30-11:55 | ºñ¸¸ÀÇ Ãֽž๰ġ·á | È«Á¤¿Ï Àͻ꺴¿ø | 11:30-11:55 | Learning Problems in Epilepsy | ¹ÚÀÌÁø °¡Å縯ÀÇ´ë |
11:55-12:20 | ºñ¸¸ Ä¡·áÀÇ ÀÓ»ó½ÇÁ¦ | ÀÓ¼ö±Ù ¿¡½ºÁöSG Á¤½Å°Ç°ÀÇÇаú | 11:55-12:20 | Behavior Problems in Epilepsy | ¾çÂù¸ð ¿ø±¤ÀÇ´ë |
12:20-12:30 | Q & A | 12:20-12:30 | Q & A | ||
Luncheon Symposium | ÁÂÀå : ÇÏÁöÇö °Ç±¹ÀÇ´ë | ||||
12:30-13:30 | Optimizing anti-depressant treatment for patientswith MDD: Take care of more than mood symptom with Vortioxetine | ±è¼±¹Ì Áß¾ÓÀÇ´ë | |||
13:30-13:40 | Coffee break | ||||
Çмú´ëȸ »çȸ : °¿ø¼· °æÈñÀÇ´ë |
Çмú´ëȸ »çȸ : À̾ƶó °æÈñÀÇ´ë | ||||
Symposium ¥° Medical Conditions Mimicking Psychiatric Disorders |
ÁÂÀå : ¼ÛÁö¿µ ¼¿ï¼º½Éº´¿ø / ÇÏÁöÇö °Ç±¹ÀÇ´ë |
Symposium ¥± Issues in Consultation-Liaison Psychiatry |
ÁÂÀå : ÇÑÁøÈñ ÆòÅüº¸ðº´¿ø / ±èÁ¾Èç ±¹¸³¾Ï¼¾ÅÍ | ||
13:40-14:05 | Functional Neurological Symptom Disorder: Update on Evaluation and Management | ¹é¸íÀç °æÈñÀÇ´ë | 13:40-14:05 | Chemotherapy Side Effects and Psychotropics | ÀÌÇöÁ¤ ±¹¸³¾Ï¼¾ÅÍ |
14:05-14:30 | Dementia or Primary Psychiatric Disorder? | ½Åö¹Î °í·ÁÀÇ´ë | 14:05-14:30 | Psychotropics and Cardiovascular Considerations | ±è¿øÇü ÀÎÇÏÀÇ´ë |
14:30-14:55 | Autoimmune Encephalopathywith Psychosis | °¿ø¼· °æÈñÀÇ´ë | 14:30-14:55 | Psychotropics and Bone Health | ÀÌ»ó¹Î °æÈñÀÇ´ë |
14:55-15:05 | Q & A | 14:55-15:05 | Q & A | ||
15:05-15:15 | Coffee break | 15:05-15:15 | Coffee break | ||
Symposium ¥² Biological Mechanism Underlying Psychosomatic Medicine |
ÁÂÀå : ±èÁ¾¿ì °æÈñÀÇ´ë / ÇÑâ¼ö °í·ÁÀÇ´ë |
Symposium ¥³ Intervention outcomes on Mental Health |
ÁÂÀå : ÀÌ°æ±Ô ´Ü±¹ÀÇ´ë / ÀÌ°ÁØ ÀÎÁ¦ÀÇ´ë | ||
15:15-15:40 | Brain-Gut Connection/Axis | Àå½ÂÈ£ ¿ø±¤ÀÇ´ë | 15:15-15:40 | Effects of Exercise/Physical Activity on Mental Health | º¯¼±Á¤ °¡Å縯ÀÇ´ë |
15:40-16:05 | Brain-Heart Connection/Axis | ¿ÀÁÖ¿µ ¿¬¼¼ÀÇ´ë | 15:40-16:05 | Effects of Diet/Nutrition on Mental Health | ¹ÚÇý¿¬ ¼¿ïÀÇ´ë |
16:05-16:30 | Brain-Lung Connection/Axis | À̾ƶó °æÈñÀÇ´ë | 16:05-16:30 | Impacts of Social Isolation on Mental Health | ÃÖÀç¿ø À»ÁöÀÇ´ë |
16:30-16:40 | Q & A | 16:30-16:40 | Q & A | ||
16:40 | Æóȸ ¹× Á¤±âÃÑȸ | 16:40 | Æóȸ ¹× Á¤±âÃÑȸ |
2022³â ⸳ 30Áֳ⠱â³ä Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°è Çмú´ëȸ
2022³â 6¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå ¼ÕÀαâ
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå Á¤Á¾Çö
PROGRAM | ||
08:30-09:00 | µî·Ï | |
09:00-09:10 | °³È¸»ç | ¼ÕÀαâ / ȸÀå, °è¿äº´¿ø |
Àλ縻 | Á¤Á¾Çö / ÀÌ»çÀå, °¡Å縯ÀÇ´ë |
A·ë | B·ë | ||||
Symposium 1 ¿¬±¸±â±Ý ¼öÇýÀÚ¹ßÇ¥ | ÁÂÀå : Á¤Á¾Çö °¡Å縯ÀÇ´ë / ¼ÕÀα⠰è¿äº´¿ø »çȸ : Áö¼öÇõ °í·ÁÀÇ´ë |
Symposium¥± Dizziness | ÁÂÀå : ÀºÇåÁ¤ ´ëÀÚÀκ´¿ø / ÀÌ°æ±Ô ´Ü±¹ÀÇ´ë »çȸ : ½Åö¹Î °í·ÁÀÇ´ë |
||
09:10-09:25 | ÇãÇ÷¼º ½ÉÁúȯ¿¡¼ ½É¸®Àû µð½ºÆ®·¹½º¿¡ µû¸¥ ÀÓ»ó ¾ç»óÀÇ Â÷ÀÌ | ±èż® / °¡Å縯ÀÇ´ë | 09:10-09:35 | ±Í ¿¬°ü ¾îÁö·³Áõ ȯÀÚ Áø´Ü°ú Ä¡·á | ¼¸íȯ / ¼¿ïÀÇ´ë À̺ñÀÎÈÄ°ú |
---|---|---|---|---|---|
09:25-09:40 | º¥Á¶µð¾ÆÁ¦ÇÉ Áß´Ü ¸Þ´º¾ó | °µîÇö / ¼¿ïÀÇ´ë | |||
09:40-09:55 | ¿ì¿ïÁõ û¼Ò³â¿¡¼ÀÇ ÀÏÁֱ⠸®µë º¯È | À̹®¼ö / °í·ÁÀÇ´ë | 09:35-10:00 | ³úÇ÷°üÁúȯ/ÅðÇ༺³úÁúȯ ¿¬°ü ¾îÁö·³Áõ ȯÀÚ Áø´Ü°ú Ä¡·á | À̼±¿í / °í·ÁÀÇ´ë ½Å°æ°ú |
09:55-10:10 | ±âÁ¸ ±Ù°ÅÀÇ Ã¼°èÀû °ËÅä ¹× ÇÕ¼ºÀ» ÅëÇÑ ¡®Ç×Á¤½Åº´¾à¹° À¯µµ¼º °íÇÁ·Ñ¶ôƾÇ÷Áõ¡¯ÀÇ ÀÓ»óÁø·áÁöħ °³¹ß | ±è¼±¹Ì / Áß¾ÓÀÇ´ë | 10:00-10:25 | Á¤½Å½ÅüÀå¾Ö Áõ»óÀ¸·Î¼ÀÇ ¾îÁö·³Áõ ȯÀÚ Áø´Ü°ú Ä¡·á | ¹ÚÇý¿¬ / ¼¿ïÀÇ´ë |
10:10-10:25 | ¿Ü»óÈÄ ½ºÆ®·¹½º ȯÀÚÀÇ ½ÅüÁõ»ó ÁõÆø Á¤µµ¿Í ÀÎÁöÁ¤¼Á¶Àý Àü·« | ±ÇÁÖÇÑ / ÀüºÏÀÇ´ë | 10:25-10:40 | Q & A | |
10:25-10:40 | ¼Ò¾Æû¼Ò³â ¿ì¿ïÁõ¿¡¼ µ¿¹ÝµÈ ±â´É¼º À§ÀåÁúȯ | ¾çÂù¸ð / ¿ø±¤ÀÇ´ë | |||
10:40-10:50 | Coffee break | 10:40-10:50 | Coffee break | ||
Symposium¥² Sex & Gender in Psychiatry |
ÁÂÀå : ³²¹ü¿ì °Ç±¹ÀÇ´ë / À̱¤Çå µ¿±¹ÀÇ´ë »çȸ : º¯¼±Á¤ °¡Å縯ÀÇ´ë |
Symposium¥³ Á¤½Å½ÅüÁúȯ¿¡¼ÀÇ ºñ¾à¹°ÇÐÀû Ä¡·á, µðÁöÅÐ Ä¡·áÁ¦ |
ÁÂÀå : °í¿µÈÆ °í·ÁÀÇ´ë / ÃÖÁØÈ£ ÇѾçÀÇ´ë »çȸ : ¾çÂù¸ð ¿ø±¤ÀÇ´ë |
||
10:50-11:15 | Special population: LGBTQ+ | À±Çö¹è / ¼¿ï´ë ÀÇÇб³À°½Ç | 10:50-11:15 | ´ç´¢¿¡¼ÀÇ digital therapeutics | ·ùÇýÁø / °í´ë±¸·Î ³»ºÐºñ³»°ú |
11:15-11:40 | Epidemiology of psychiatric disorder in LGBTQ+ & Beyond | ÀåâÇö / »ì¸²ÀÇ¿ø | 11:15-11:40 | ¸¸¼ºÅëÁõ Ä¡·á¿ë ½Å°æÀÚ±âÀÚ±Ø(NMS) Àåºñ | ¹Î°æÈÆ / ºÐ´çÂ÷º´¿ø ÀçÈ°ÀÇÇаú |
11:40-12:05 | ¼ºº° ºÒÄè°¨¿¡¼ÀÇ È£¸£¸ó Ä¡·á ¹× LGBT people°úÀÇ ¸é´ã | ÃÖÀα¤ / ÃÖÀα¤Á¤½Å°Ç°ÀÇÇаú | 11:40-12:05 | ¸¶À½Ã¬±è¸í»ó | À¯Á¤Àº / ¸¶º¸ |
12:05-12:20 | Q & A | 12:05-12:20 | Q & A | ||
ISS 1 | Management of MDD patients | ÁÂÀå : Á¤Á¾Çö / °¡Å縯ÀÇ´ë | ISS 2 | A New Normal Antidepressant | ÁÂÀå : ÇÏÁöÇö °Ç±¹ÀÇ´ë |
12:20-12:50 | Optimizing treatment for patients with MDD: The advantage of 20mg dose of Vortioxetine | È«Á¤¿Ï / Àͻ꺴¿ø | 12:20-12:50 | A Paradigm Shift to Recover from Depression | À̹®¼ö / °í·ÁÀÇ´ë |
12:50-13:20 | Emotional blunting and Anhedonia management with Vortioxetine | ±è¼±¹Ì / Áß¾ÓÀÇ´ë | 12:50-13:20 | Therapeutic Advantage of Agomelatine in Treating Depression | °¿ø¼· / °æÈñÀÇ´ë |
13:20-13:40 | Á¤½Å½ÅüÀÇÇÐ ±³°ú¼ ÃâÆDZâ³äȸ | ||||
13:40-14:00 | Coffee break | ||||
Symposium¥´ ÀϺ»°úÀÇ ±³·ù ½ÉÆ÷Áö¾ö |
ÁÂÀå : ±èÀÇÁß À»ÁöÀÇ´ë / Àü´öÀÎ ÇѸ²ÀÇ´ë |
Symposium¥µ ºñ¸¸ÀÇ Á¤½Å½ÅüÀÇÇÐÀû ÀÌÇØ |
ÁÂÀå : ÀÌ»ó¿ ¿ø±¤ÀÇ´ë / ¼Á¤¼® Áß¾ÓÀÇ´ë | ||
14:00-14:30 | Comparison of depression and delirium with Alzheimer¡¯s Disease using cognitive function tests | Dr. Taro Fukue / Yokohama National University | 14:00-14:25 | ºñ¸¸ ¹× ´ë»çÁúȯÀÇ ÀÌÇØ | ¾ç¿¹½½ / °¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú |
14:30-15:00 | Development and Clinical Use of a Dietary Management App for Eating Disorders in Japan | Dr. Tsuneo Yamauchi / Osaka Metopolitan University | 14:25-14:50 | ºñ¸¸ÀÇ ¾à¹°ÇÐÀû Ä¡·á | ¼ºÇü¸ð / ¼øõÇâÀÇ´ë |
14:50-15:00 | Q & A | ||||
Symposium¥¶ Á¤½Å°ú¿¡¼ ¾Ë¾Æ¾ß ÇÏ´Â Àå¾ÖÁø´Ü ¹× º¹Áö ÇýÅà |
ÁÂÀå : °¿ø¼· °æÈñÀÇ´ë / ÀÌ°ÁØ ÀÎÁ¦ÀÇ´ë »çȸ : À̰Ǽ® ÇѾçÀÇ´ë |
Symposium¥· ÇâÈÄÀÇ Á¤½Å½ÅüÀÇÇÐÀÇ ¹Ì·¡ |
ÁÂÀå : ÇÏÁöÇö °Ç±¹ÀÇ´ë / ±èÁ¾Èç ±¹¸³¾Ï¼¾ÅÍ »çȸ : À̹®¼ö °í·ÁÀÇ´ë |
||
15:00-15:25 | ¼Ò¾Æ | ÀÌÁ¾ÇÏ / °í·ÁÀÇ´ë | 15:00-15:25 | Á¤½Å½ÅüÀÇÇÐÀÇ ±³À° | ¿ÀÈ«¼® / °Ç¾çÀÇ´ë |
15:25-15:50 | ¼ºÀαâ | Àå½ÂÈ£ / ¿ø±¤ÀÇ´ë | 15:25-15:50 | Á¤½Å½ÅüÀÇÇÐ ºÐ¾ß¿¡¼ÀÇ ¿¬±¸ È°¼ºÈ ¹æ¾È | ÇÔºÀÁø / ¼¿ïÀÇ´ë |
15:50-16:15 | ³ëÀÎ (Ä¡¸Å±¹°¡Ã¥ÀÓÁ¦) | ¾çÇöÁÖ / Á¦ÁÖÀÇ´ë | 15:50-16:15 | Á¤½Å½ÅüÀÇÇÐÀû ÀÚ¹®¿¡¼ÀÇ ÀûÁ¤ ¼ö°¡¶õ | À̺´Ã¶ / ÇѸ²ÀÇ´ë |
16:15-16:30 | Q & A | 16:15-16:30 | Q & A | ||
16:30 ~ | ÃÑȸ ¹× 30Áֳ⠱â³ä½Ä | ||||
Plenary lecture | ÀÌ»ó¿ / Çѱ¹Á¤½Å½ÅüÃѼ À§¿øÀå, ¿ø±¤ÀÇ´ë | ||||
ÀÓ»ó³úÆÄÀ§¿øȸ °æ°úº¸°í | ÀºÇåÁ¤ / ÀÓ»ê³úÆÄ À§¿øÀå, ´ëÀÚÀκ´¿ø | ||||
Á¤½Å½ÅüÀü¹®°¡°úÁ¤ °æ°úº¸°í | °í¿µÈÆ / Àü¹®°¡°úÁ¤ À§¿øÀå, °í·ÁÀÇ´ë |
2021 Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°è Çмú´ëȸ ¹× ¿¬¼ö±³À°
2021³â 11¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå ¼ÕÀαâ
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå Á¤Á¾Çö
ÀÓ»ó³úÆÄ ½Ç½À¿öÅ©¼¥ÀÇ »çÀüµî·Ï ¾È³»
Çмú´ëȸ ÄÁº¥¼ÇȦ »çȸ : ÇмúÀÌ»ç À̹®¼ö |
¿¬¼ö±³À° ´ëȸÀÇ½Ç »çȸ : ±³À°ÀÌ»ç °¿ø¼· |
||||
Symposium 1 µÎºÎ ¿Ü»óÀÇ Á¤½ÅÀÇÇÐÀû ÀÌÇØ |
ÁÂÀå : ±èÇö¿ì ¾Æ¶÷¸ÞµðÄú´¿ø / ¼Á¤¼® Áß¾ÓÀÇ´ë |
¿¬¼ö±³À°1 Neurological Conditions and Their Psychiatric Manifestations |
ÁÂÀå : ¹Ú¹Îö ½Å¼¼°èÈ¿º´¿ø / ¼ÕÀα⠰è¿äº´¿ø | ||
09:10-09:35 | µÎºÎ ¿Ü»óÀÇ Á¤½Å°Ç°ÀÇÇÐÀû Æò°¡ | ½Å»óÈ£ / °í´ë¾È»êº´¿ø | 09:10-09:35 | Psychiatric Aspects of Parkinson¡¯s Disease | Àӿ쿵 / °Ç¾çÀÇ´ë |
---|---|---|---|---|---|
09:35-10:00 | °æµµ µÎºÎ ¿Ü»óÀÇ ÀÌÇØ | Á¤±ÔÇÏ / °í´ë±¸·Îº´¿ø ½Å°æ¿Ü°ú | 09:35-10:00 | Psychiatric Aspects of Epilepsy | ¾öÀ¯Çö / °¡Å縯ÀÇ´ë |
10:00-10:25 | Á¤½Å°úÀû Áõ»óÀ» È£¼ÒÇÏ´Â µÎºÎ ¿Ü»ó ȯÀÚµéÀÇ °ü¸® | ±èÁØÇü / °í´ë±¸·Îº´¿ø | 10:00-10:25 | Catatonia, Neuroleptic Malignant Syndrome, and Serotonin syndrome | À̰Ǽ® / ÇѾçÀÇ´ë |
10:25-10:40 | Q & A | 10:25-10:40 | Q & A | ||
10:40-10:50 | Coffee break | 10:40-10:50 | Coffee break | ||
Symposium 2 Á¤½Å°ú¿¡¼ ÈçÇÏ°Ô ´Ù·ç´Â ¹®Á¦¿¡ ´ëÇÑ ´Ù¾çÇÑ Á¢±Ù¹ý |
ÁÂÀå : ÇÑÁøÈñ ÆòÅüº¸ðº´¿ø / Àü´öÀÎ ÇѸ²ÀÇ´ë |
¿¬¼ö±³À°2 Women¡¯s Mental Health and Reproductive Psychiatry |
ÁÂÀå : ÀÌ°æ±Ô ´Ü±¹ÀÇ´ë / ³²¹ü¿ì ÃæÁְǴ뺴¿ø | ||
10:50-11:10 | PPTSD¿¡¼ stellate ganglion block | À±¿ëÇö / ÀÎõÅ͹̳ÎÁ¤Çü¿Ü°ú | 10:50-11:15 | Psychiatric Disorders during pregnancy and the postpartum period | ½Åö¹Î / °í·ÁÀÇ´ë |
11:10-11:30 | ºñ¸¸¿¡¼ ºñ°æ±¸¿ë ¾à¹° ¹× »ýÈ°½À°ü Á¶ÀýÀ» ÅëÇÑ °ü¸® | ÃÖ¿øö / ÀÌ¿ÀÀÇ¿ø | 11:15-11:40 | Psychiatric Symptoms and disorders in perimenopause | ±è¼±¹Ì / Áß¾ÓÀÇ´ë |
11:30-11:50 | »êÈÄ¿ì¿ïÁõ¿¡¼ brexanoloneÀÇ Àû¿ë | È«Á¤¿Ï / Àͻ꺴¿ø | 11:40-12:05 | Premenstrual dysphoric disorder and psychotropic medications in Pregnancy | °¿ø¼· / °æÈñÀÇ´ë |
11:50-12:10 | ³Ä¡¼º ƽÀå¾Ö¿¡¼ÀÇ DBS | ÀÌÁ¤ÇÑ / ¼¼ºê¶õ½ºº´¿ø | |||
12:10-12:20 | Q & A | 12:05-12:20 | Q & A | ||
ISS 1 | Agomelatine, for Better Choice | Á¤Á¾Çö / °¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø | ISS 2 | Current Challenges and Implication for Clinical Practice | ÀÌ»ó¿ / ¿ø±¤ÀÇ´ë |
12:20-12:50 | Anxiety & Depression in the COVID Pandemia | È«Á¤¿Ï / Àͻ꺴¿ø | 12:20-12:50 | How to manage ¡°Anhedonia and Emotional blunting¡± with Vortioxetine? | °¿ø¼· / °æÈñÀÇ´ë |
12:50-13:20 | Benefits of Agomelatine treatment strategies | ±è¼±¹Ì / Áß¾ÓÀÇ´ë | 12:50-13:20 | When could Vortioxetine be a relevant treatment option? | À̹®¼ö / °í·ÁÀÇ´ë |
13:20-13:30 | Coffee break | 13:20-14:00 | Coffee break | ||
Symposium 3 A close look at the effects of the medicine on the mental health |
ÁÂÀå : Á¶¼÷Çà ¾Æ¸§´Ù¿î ¹Ì·¡ÀÇ¿ø / ÀÌ°ÁØ ÀÎÁ¦ÀÇ´ë |
ÀÓ»ó³úÆÄÀ§¿øȸ ¿öÅ©¼¥ Understanding and Real Practice of tDCS (Transcranial Direct Current Stimulation) |
|||
13:30-13:55 | Effects of antiepileptic drug on the mental health | ÃÖÁØÈ£ / ÇѾçÀÇ´ë | |||
13:55-14:20 | Effect of anti-tumor immunotherapy on the mental health | ±è¼±¿µ / Àü³²ÀÇ´ë |
Sessoin 1 Understanding of tDCS |
ÁÂÀå : ÀºÇåÁ¤ ´ëÀÚÀκ´¿ø | |
14:20-14:45 | Effect of antibiotics and antiviral agents on the mental health | ±è¿øÇü / ÀÎÇÏÀÇ´ë | |||
14:45-15:00 | Q & A | 14:00-14:40 | Theoretical background and present of tDCS | À̱â¿ø / ¿ÍÀ̺극ÀÎ | |
15:00-15:10 | Coffee break | 14:40-15:20 | Latest clinical trial and indications for tDCS | ³ë´ë¿µ / ÇѸ²ÀÇ´ë | |
Symposium 4 Management of chronic pain |
ÁÂÀå : À¯¹üÈñ À¯¹üÈñÁ¤½Å°Ç°ÀÇÇаú ÀÇ¿ø / ÇÏÁöÇö °Ç±¹ÀÇ´ë | 15:20-15:30 | Q & A | ||
15:30-15:40 | Coffee break | ||||
15:10-15:35 | ¸¶ÃëÅëÁõÀÇÇаú¿¡¼ º¸´Â ¸¸¼º ÅëÁõ °üÁ¡ | ÃÖ»ó½Ä / °í´ë±¸·Îº´¿ø ¸¶ÃëÅëÁõÀÇÇаú |
Sessoin 2 Real Practice of tDCS |
||
15:35-16:00 | Somatic symptom disorder with predominant pain | ¼½Â¿Ï / °µ¿¼º½Éº´¿ø | |||
16:00-16:25 | Psychiatric management of chronic pain | ÀÌ°æȯ / ±è¿ø¹¬±â³äºÀ»ýº´¿ø | |||
16:25-16:40 | Q & A | 15:40-16:40 | Real Practice of tDCS Instrument / ½Ç½ÀÁöµµ | ¿ÍÀ̺극ÀÎ | |
16:40 | Æóȸ | 16:40 | Æóȸ |
2021 Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°è Çмú´ëȸ ¹× ¿¬¼ö±³À°
2021³â 4¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå ÀºÇåÁ¤
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå Á¤Á¾Çö
¡Ø °¨¿°¿¹¹æÀ» À§ÇÏ¿© [»ýÈ°¼Ó °Å¸® µÎ±â Áöħ]À» ÁؼöÇÏ¿© ¾ÈÀüÇÏ°Ô °ÀǸ¦ ÁøÇàÇÏ°íÀÚ »çÀüµî·ÏÀº Á¤¿ø 100¸í µî·Ï½Ã ¸¶°¨ ÇÏ°Ú½À´Ï´Ù.
¿¬¼ö±³À° ÄÁº¥¼ÇȦ | ÀÓ»ó³úÆÄÀ§¿øȸ fNIRS ¿öÅ©¼¥ ´ëȸÀÇ½Ç | ||||
¿¬¼ö±³À° I. Persistent somatic symptoms at the medical-psychiatric boundary |
ÁÂÀå : Àü´öÀÎ / ÇѸ²ÀÇ´ë |
Session I. Introduction to fNIRS(functional near-infrared spectroscopy) |
ÁÂÀå : ÀºÇåÁ¤ / ´ëÀÚÀκ´¿ø | ||
09:30-09:50 | Understanding of medically unexplained symptoms | ¹ÚÇý¿¬ / ¼¿ïÀÇ´ë | 09:30-10:00 | Description, history and spectroscopic techniques of fNIRS | ±èÀç¸í / ¿ÀºñÀÌ·¦ |
---|---|---|---|---|---|
09:50-10:10 | Diagnosis and evaluation of somatic symptom disorder | Àå½ÂÈ£ / ¿ø±¤ÀÇ´ë | 10:00-10:30 | Data analysis in fNIRS and apply to cognitive science | ÃÖÁ¾°ü / ¿ÀºñÀÌ·¦ |
10:10-10:30 | Management of somatic symptom disorder | ÀüÈ«ÁØ / °Ç±¹ÀÇ´ë | 10:30-10:40 | Q & A | |
10:30-10:40 | Q & A | 10:40-10:50 | Coffee break | ||
10:40-10:50 | Coffee break | ||||
¿¬¼ö±³À° II. Medical Considerations in psychiatric disorders |
ÁÂÀå : ¼ÕÀαâ / °è¿äº´¿ø |
Session II. Clinical Cases and Practical Learning of fNIRS |
ÁÂÀå : À̽Âȯ / ÀÎÁ¦ÀÇ´ë | ||
10:50-11:15 | Psychotic disorders due to medical illnesses | ±è¼º¹Î / °¡Å縯ÀÇ´ë | 10:50-11:20 | Use of VR working memory task and fNIRS to assess brain hemodynamic responses to Methylphenidate in ADHD children | ±èÀºÁÖ / ¿¬¼¼ÀÇ´ë |
11:15-11:40 | Mood disorders due to medical illnesses | ÃÖ°ü¿ì / °í·ÁÀÇ´ë | 11:20-11:50 | Demo session (NIRSIT LITE with monitoring app, cognitive app) | Á¶¿ø»ó/ ¿ÀºñÀÌ·¦ |
11:40-11:50 | Q & A | 11:50-12:00 | Q & A | ||
11:50-12:00 | Coffee break | ÀÓ»ó³úÆĽǽÀ¿öÅ©¼¥ »çÀüµî·Ï e-mail Á¢¼ö¹Ù¶ø´Ï´Ù. (pmcnp96@gmail.com, ÀºÇåÁ¤) | |||
Mutual visiting program. | Mutual visiting program. Japanese Society of Gene | ||||
¡Ø »çÀü ³ìÈµÈ µ¿¿µ»óÀ¸·Î ÁøÇàµË´Ï´Ù. | |||||
12:00-12:20 | A retrospective study of the effect of background factors on seizure quality in ECT, | retrospective study of the effect of background factors on seizure quality in | |||
12:20-12:40 | Serum CK levels in 72 patients with malignant syndrome, rhabdomyolysis, and water intoxication | Hidenori Matsunaga / Division of Psychiatry,Osaka General Medical Center | |||
12:40-12:50 | Coffee break | ||||
ISS I. Management of TRD/MDSI patients |
ÁÂÀå : ÀÌ»ó¿ / ¿ø±¤ÀÇ´ë |
ISS II. Effect of BUSPAR in Anxiety with psychosomatic symptoms |
ÁÂÀå : Á¤Á¾Çö / °¡Å縯ÀÇ´ë | ||
12:50-13:15 | Psychedelic Drugs: Lessons From SPRAVATO | À̹®¼ö / °í·ÁÀÇ´ë | 12:50-13:15 | Differential Benefits of BUSPAR | È«Á¤¿Ï / Àͻ꺴¿ø |
13:15-13:40 | SPRAVATO clinical setting &real practice for TRD/MDSI patients | °¿ø¼·/ °æÈñÀÇ´ë | 13:15-13:40 | The usefulness of buspirone in treatment somatic symptoms | Àå½ÂÈ£ / ¿ø±¤ÀÇ´ë |
13:40-13:50 | Q & A | 13:40-13:50 | Q & A | ||
13:50-14:00 | Coffee break | 13:50-14:00 | Coffee break |
Çмú´ëȸ | Çмú´ëȸ | ||||
Symposium I. Sex hormonal effect on women¡¯s mental health |
ÁÂÀå : ³²¹ü¿ì / °Ç±¹ÀÇ´ë, °í¿µÈÆ / °í·ÁÀÇ´ë |
Symposium II. Mortality in psychiatric patients |
ÁÂÀå : ±èÀÇÁß / À»ÁöÀÇ´ë, ±èÁ¾Èç / ±¹¸³¾Ï¼¾ÅÍ | ||
14:00-14:25 | Effects of contraception on psychiatric problem | À±¼¿µ/ ´ë±¸°¡Å縯ÀÇ´ë | 14:00-14:25 | Cancer mortality | ±èÇöÁø / Ãæ³²ÀÇ´ë |
---|---|---|---|---|---|
14:25-14:50 | Hormonal background and treatment of perinatal depression | ±è¼±¹Ì / Áß¾ÓÀÇ´ë | 14:25-14:50 | Drug-related mortality in psychiatric patients | ±è±â¿ø / Áß¾Óº¸Èƺ´¿ø |
14:50-15:15 | Cognition and mood in perimenopausal women | À̼ÒÈñ / ±¹¸³Áß¾ÓÀÇ·á¿ø | 14:50-15:15 | Mortality in schizophrenia and bipolar disorder | ±èÁØÇü / °í·ÁÀÇ´ë |
15:15-15:30 | Q & A | 15:15-15:30 | Q & A | ||
15:30-15:50 | Coffee break | 15:30-15:50 | Coffee break | ||
Symposium III. Á÷¹«½ºÆ®·¹½ºÀÇ Á¤½ÅÀÇÇÐÀû Á¢±Ù |
ÁÂÀå : ÀÌ°æ±Ô / ´Ü±¹ÀÇ´ë, À̱¤Çå / µ¿±¹ÀÇ´ë |
Symposium IV. Á¤½Å½ÅüÀÇÇÐÀÇ Àü°øÀÇ¿¡¼ÀÇ ±³À°? ¾î¶»°Ô |
ÁÂÀå : ±èÁ¾¿ì / °æÈñÀÇ´ë, ¼ÛÁö¿µ / ¼ÛÁö¿µÁ¤½Å°Ç°ÀÇÇаúÀÇ¿ø | ||
15:50-16:15 | EAP »ç¾÷ÀÇ ¿î¿µ °æÇè°ú ½ÇÁ¦ | ±èÁ¤Çö / ¼¿ïÀÇ´ë | 15:50-16:15 | Àü°øÀÇ Âü¿© º´µ¿consult¿¡¼ÀÇ Å¸°ú¿ÍÀÇ ÀÇ»ç¼ÒÅë | ±èż® / °¡Å縯ÀÇ´ë |
16:15-16:40 | Á÷ÀåÀÎ Á¤½Å°Ç°°ü¸®ÀÇ ½ÇÁ¦ : °ø°ø Á¤½Å º¸°Ç ¿µ¿ªÀ» Áß½ÉÀ¸·Î | °ÇÑ°íÀººñ / ±¹¸³³ªÁÖº´¿ø | 16:15-16:40 | ÀÀ±Þ½Ç¿¡¼ÀÇ Å¸°ú¿ÍÀÇ ÀÇ»ç ¼ÒÅë | ÃÖÀç¿ø / À»ÁöÀÇ´ë |
16:40-17:05 | ±â¾÷ÀÇ Á÷ÀåÁ¤½Å°Ç° °ü¸® ¹æ¾ÈÀÇ ½ÇÁ¦ | Àü»ó¿ø / ¼º±Õ°üÀÇ´ë | 16:40-17:05 | ¹Ù²î´Â ¼ö·Ãȯ°æ ÇÏ¿¡¼ ÇÊ¿äÇÑ Àü°øÀÇ ¼ö·Ã ¹æ½Ä º¯È | ¿ÀÈ«¼® / °Ç¾çÀÇ´ë |
17:05-17:20 | Q & A | 17:05-17:20 | Q & A | ||
17:20-17:30 | ½Ã»ó ¹× Æóȸ | 17:20-17:30 | ½Ã»ó ¹× Æóȸ |
2020 Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ¿Â¶óÀÎ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
2020³â 10¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå ÀºÇåÁ¤
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå Á¤Á¾Çö
¿¬ ¼ö ±³ À° | ÁøÇà : °¿ø¼· / ±³À°ÀÌ»ç, °æÈñÀÇ´ë | |
09:00-09:10 | °³È¸»ç | ÀºÇåÁ¤ / ȸÀå, ¿¹¼öº´¿ø |
09:10-10:35 | ¿¬¼ö±³À° I. Medical and Neurological Disorders that Present with Psychiatric Symptoms | ÁÂÀå : ³²¹ü¿ì / °Ç±¹ÀÇ´ë |
09:10-09:35 | Post Stroke Depression Frequently Overlooked, Undiagnosed, Untreated | ÀÌ»ó¹Î / °æÈñÀÇ´ë |
09:35-10:00 | Treatment issues in the cardiac patient | ÃÖÀç¿ø / À»ÁöÀÇ´ë |
10:00-10:25 | Management of psychiatric symptoms in fibromyalgia patient | ³ªÀºÁø / ¼¿ïÀÇ·á¿ø |
10:25-10:35 | Áú¹® ¹× Åä·Ð | ³ªÀºÁø / ¼¿ïÀÇ·á¿ø |
10:35-10:45 | Coffee break | |
10:45-12:10 | ¿¬¼ö±³À° II. Difficult Situations In Consultation-Liaison Psychiatry | ÁÂÀå : ¼ÕÀαâ / °è¿äº´¿ø, ±èÀÇÁß / À»ÁöÀÇ´ë |
10:45-11:10 | Dilemmas in the assessment and management of pain in the palliative care and oncology settings | À̰Ǽ® / ÇѾçÀÇ´ë |
11:10-11:35 | Behavioral control in Traumatic brain injury patient | ÀüÈ«ÁØ / °Ç±¹ÀÇ´ë |
11:35-12:00 | Psychotropic drug prescribing in Artificial Kidney Unit | °¿ø¼· / °æÈñÀÇ´ë |
12:00-12:10 | Áú¹® ¹× Åä·Ð | |
12:10-12:20 | °ø·ÎÆÐ ¼ö¿© | |
12:20-13:00 | Lunch time (online poster tour) |
ÇÐ ¼ú ´ë ȸ | ÁøÇà : À̹®¼ö / ÇмúÀÌ»ç, °í·ÁÀÇ´ë | |||
13:00-14:00 | How to Manage The Mental Disorder and GI Complications by Aripipraozole and Rebamipide | ÁÂÀå : Á¤Á¾Çö / ÀÌ»çÀå, °¡Å縯ÀÇ´ë | ||
13:00-13:20 | The Clinical Benefits of Abilify Maintena in The Treatment of Schizophrenia | ±è¿øÇü / ÀÎÇÏÀÇ´ë | ||
13:20-13:40 | The Clinical Benefits of Abilify in The Treatment of MDD : Symptom Based Approach | ±è¼±¹Ì / Áß¾ÓÀÇ´ë | ||
13:40-14:00 | Brain-gut Microbiome and GI Medication in Psychiatric Disorders | Àå½ÂÈ£ / ¿ø±¤ÀÇ´ë | ||
14:00-14:10 | Coffee break | |||
Room 1 | Room 2 | |||
14:10-15:40 | Symposium 1. Àå±â À̽ÄÀÇ Á¤½ÅÀÇÇÐÀû ÀÚ¹® | ÁÂÀå : ÇÏÁöÇö / °Ç±¹ÀÇ´ë, ±èż® / °¡Å縯ÀÇ´ë | Symposium 2. Cognition and sleep | ÁÂÀå : ÀÌ»ó¿ / ¿ø±¤ÀÇ´ë, ÃÖÁØÈ£ / ÇѾçÀÇ´ë |
14:10-14:35 | ±¹³»¿¡¼ÀÇ Àå±â ÀÌ½Ä ÇöȲ | ȲÁÖÈñ/ ±¹¸³ Àå±âÁ¶Á÷Ç÷¾×°ü¸®¿ø | Association of sleep characteristics and cognition in elderly | ¼½Â¿Ï / ÇѸ²ÀÇ´ë |
14:35-15:00 | Psychiatric comorbidities among patients undergoing liver transplantation in South Korea | ÇãÀ缺/ ¾ÆÁÖ´ë ¹æ»ç¼±Á¾¾çÇаú | Sleep problems associated with BPSD | ÀÌ°À± / ºÎ»êÀÇ´ë |
15:00-15:25 | À̽Ŀ¡ ÇÊ¿äÇÑ Á¤½Å°úÀû ÀÚ¹® Æò°¡ (°£À̽Ä) | À̹®¼ö/ °í·ÁÀÇ´ë | Cognition and sleep-disordered | ÀÌ°æȯ / ºÀ»ýº´¿ø |
15:25-15:40 | Áú¹® ¹× Åä·Ð | Áú¹® ¹× Åä·Ð | ||
15:40-16:00 | Coffee break | |||
16:00-17:30 | Symposium 3. Psychosomatics in Motion - Bringing Physical movement to psychiatry | ÁÂÀå : ÇÔºÀÁø / ¼¿ïÀÇ´ë, ÀÌ°ÁØ / ÀÎÁ¦ÀÇ´ë | Symposium 4. ½ºÅ×·ÎÀ̵å È£¸£¸ó°ú Á¤½ÅÀÇÇÐ | ÁÂÀå : ÀºÇåÁ¤ / ¿¹¼öº´¿ø, ¼Á¤¼® / °Ç±¹ÀÇ´ë |
16:00-16:25 | ¿îµ¿°ú Á¤½Å°Ç° - ¿îµ¿ ó¹æÀÇ ½ÇÁ¦ | ¹ÚÀçÇö/ ÇѾçÀÇ´ë ÀçÈ°ÀÇÇаú | Steroid¿Í ÀÎÁö | ¿À´ëÁ¾ / ¼¿ïÀÇ´ë |
16:25-16:50 | Á¤½ÅÁúȯ ÁßÀç¹æ¹ýÀ¸·Î¼ÀÇ ¿îµ¿ | ±è¼±¹Ì/ Áß¾ÓÀÇ´ë | steroid¿Í Á¤½ÅÁõ | ÀÌÁØÈñ / ¼¿ïÀÇ´ë |
16:50-17:15 | ¿îµ¿¼º ÀÎÁöÀ§Çè ÁõÈıº - ÁÖ¸ñÇÒ ¸¸ÇÑ »õ·Î¿î Ä¡¸Å°íÀ§Ç豺 | º¯¼±Á¤/ °¡Å縯ÀÇ´ë | steroid¿Í ±âºÐÀå¾Ö | ±èÇý¿µ / ÀÎÇÏÀÇ´ë |
17:15-17:30 | Áú¹® ¹× Åä·Ð | Áú¹® ¹× Åä·Ð | ||
17:30-17:40 | Æóȸ(½Ã»ó) |
2019 Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
Psychosomatic Perspectives of Metabolic Syndrome and Pain
2019³â 04¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå Àü´öÀÎ
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå ±èÀÇÁß
»çÀüµî·Ï | ´çÀϵî·Ï | ºñ°í | |
---|---|---|---|
|
|
|
Áß½ÄÁ¦°ø |
[¿¬¼ö±³À°] »çȸ: ÇÏÁöÇö ±³À°ÀÌ»ç (°Ç±¹ÀÇÀü¿ø) |
[ÀÓ»ó³úÆÄ ÀÚ¹® ¿öÅ©¼¥ I] »çȸ: ÀºÇåÁ¤ ÀÓ»ó³úÆÄÀ§¿øÀå (¿¹¼öº´¿ø) |
||||
Evaluation and treatment of pain | ÁÂÀå: Àü´öÀÎ(ÇѸ²ÀÇ´ë) ±èÁ¾Èç(±¹¸³¾Ï¼¾ÅÍ) |
Electroencephalography Consultation in Critical Care Medicine Session I | ÁÂÀå: ÀÌ°æ±Ô(´Ü±¹ÀÇ´ë) ³²¹ü¿ì(°Ç±¹ÀÇÀü¿ø) |
||
09:30-09:55 | Physiology and evaluation of pain | Àå½ÂÈ£ (¿ø±¤ÀÇ´ë) | 09:30-10:10 | Indications in Intensive Care Unit EEG Monitoring I | Á¤Á¾Çö(°¡Å縯ÀÇ´ë) |
09:55-10:20 | Biological treatment of chronic pain | ¼Û¸¸±Ô (ûÁÖÇѱ¹º´¿ø) | 10:10-10:50 | Indications in Intensive Care Unit EEG Monitoring II | ±è¼±¹Ì(Áß¾ÓÀÇ´ë) |
10:20-10:45 | Psychosocial treatment of chronic pain | ÀÌ¿øÁØ (ÇѸ²ÀÇ´ë) | 10:50-11:00 | Áú¹®°ú Åä·Ð | |
10:45-11:10 | Recent updates in CRPS and fibromyalgia` | ±èÀçÇå (°Ç±¹ÀÇÀü¿ø ¸¶ÃëÅëÁõÀÇÇаú) | |||
11:10-11:20 | Áú¹®°ú Åä·Ð | ||||
11:20-11:30 | Coffee Break | ||||
Mutual visiting program (Japanese Society of General Hospital Psychiatry) | ÁÂÀå: ÇÑâ¼ö (°í·ÁÀÇ´ë) | ||||
11:30-11:50 | Ward rounds by psychiatric liaison team for early detection and intervention of delirium can decrease length of hospital stay | Shimpei Yamasaki (Kyoto University, Japan) | |||
11:50-12:10 | Epigenetic variation associated with the onset of postoperative delirium | Ryoichi Sadahiro (National Cancer Center, Japan) | |||
12:10-12:20 | Áú¹®°ú Åä·Ð | ||||
Luncheon Symposium and Poster Tour | ÁÂÀå: ÀÌ»ó¿ (¿ø±¤ÀÇ´ë) | ||||
12:20-13:10 | Efficacy and Safety of Agomelatine : Comparison with Other Antidepressants | ¼Á¤¼® (°Ç±¹ÀÇÀü¿ø) | |||
Special Lecture | ÁÂÀå: ±èÀÇÁß(À»ÁöÀÇ´ë) | ||||
13:10-14:00 | The link with metabolic-inflammatory systems in mood disorders | Roger Mclntyre (University of Toronto, Canada) | |||
14:00-14:10 | Coffee break |
[Çмú´ëȸ]
»çȸ: ±èż® ÇмúÀÌ»ç (°¡Å縯ÀÇ´ë) |
[ÀÓ»ó³úÆÄ ÀÚ¹® ¿öÅ©¼¥ II] »çȸ: ÀºÇåÁ¤ ÀÓ»ó³úÆÄÀ§¿øÀå (¿¹¼öº´¿ø) |
||||
Metabolic syndrome & Obesity Session I Psychosomatic Perspectives | ÁÂÀå: ÇÔºÀÁø (¼¿ïÀÇ´ë) ±èÁ¾¿ì(°æÈñÀÇ´ë) |
Electroencephalography Consultation in Critical Care Medicine Session II | ÁÂÀå: ÀÌ°ÁØ(ÀÎÁ¦ÀÇ´ë) ÃÖÁØÈ£(ÇѾçÀÇ´ë) |
||
14:10-14:35 | Psychosocial stress and metabolism | À±¼¿µ (´ë±¸°¡Å縯ÀÇ´ë) | 14:10-14:50 | EEG Interpretation | ¾öÀ¯Çö(°¡Å縯ÀÇ´ë) |
14:35-15:00 | Clinical updates of metabolic syndrome and obesity | Á¶¿µ¹Î (¼¿ïÀÇ´ë ³»ºÐºñ³»°ú) | 14:50-15:30 | Quantitative EEG | °í¿µÈÆ(°í·ÁÀÇ´ë) |
15:00-15:25 | Metabolic syndrome and obesity in psychiatry | ¹Ú¿µ¹Î (ÀÎÁ¦ÀÇ´ë)) | 15:30-15:40 | Áú¹®°ú Åä·Ð | |
15:25-15:35 | Áú¹®°ú Åä·Ð | ||||
15:35-15:45 | Coffee Break | ||||
Metabolic syndrome & Obesity Session II Management Issues | ÁÂÀå: Á¤Á¾Çö(°¡Å縯ÀÇ´ë) ¼Á¤¼®(°Ç±¹ÀÇÀü¿ø) |
||||
15:45-16:10 | Medical management of metabolic syndrome and obesity | ±è¼¼È« (°¡Å縯ÀÇ´ë °¡Á¤ÀÇÇаú) | |||
16:10-16:35 | Surgical management of obesity | ÀÌÇÑÈ« (°¡Å縯ÀÇ´ë À§Àå°ü¿Ü°ú) | |||
16:35-17:00 | Psychiatrist¡¯s role and experience of obesity management | À¯ÀºÁ¤(¼ÃÊÁÁÀºÀÇ¿ø Á¤½Å°Ç°ÀÇÇаú) | |||
17:00-17:10 | Áú¹®°ú Åä·Ð | ||||
17:10 | Æóȸ (Æ÷½ºÅÍ ¹× Çмú»ó ½Ã»ó) ¹× Á¤±âÃÑȸ |
[ Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ 2019 ÇØ¿ÜÀü¹®°¡ ÃÊû ¸¶½ºÅÍŬ·¡½º ]
ÁÖ¿ä¿ì¿ïÀå¾Ö¿¡¼ÀÇ ÀÎÁö±â´ÉÀå¾Ö¿Í Ãֽž๰ġ·á¹ý
ÁÖ¿ä¿ì¿ïÀå¾Ö¿¡¼ÀÇ ÀÎÁö±â´ÉÀå¾Ö¿Í Ãֽž๰ġ·á¹ý
2019³â 04¿ù
Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ÀÌ»çÀå ±èÀÇÁß
±³À°/±¹Á¦/Á¤º¸ÀÌ»ç ÇÏÁöÇö, À̹®¼ö, ÀÌÀçÇå
»çȸ: ÀÌÀçÇå (Á¤º¸ÀÌ»ç)
1:00~1:05 | °³È¸ ¹× Àλ縻 (ÀÌ»çÀå) |
---|---|
1:05~1:10 | °»ç ¼Ò°³ |
1:20~2:20 |
|
2:20~2:30 | Break |
2:30~3:40 |
|
3:40~3:50 | Break |
3:50~5:00 |
|
5:00~5:20 | Q&A |
»çÀüµî·Ï (Á¤½Å½ÅüÇÐȸ Ãá°èÇмú´ëȸ¿Í µ¿½Ã µî·Ï ½Ã) |
»çÀüµî·Ï (¸¶½ºÅÍŬ·¡½º¸¸ µî·Ï ½Ã) |
ÇöÀåµî·Ï (ÀÜ¿©¼®ÀÌ ÀÖÀ» °æ¿ì¿¡¸¸ °¡´É) |
|
---|---|---|---|
|
|
|
|
* µî·ÏÇϽŠºÐ²²´Â ÀÚ·áÁý, °£´ÜÇÑ °£½Ä, ÁÖÂ÷±ÇÀÌ Á¦°øµË´Ï´Ù.